Quick Takeaways
- Woodline Partners LP filed SCHEDULE 13G for Quoin Pharmaceuticals, Ltd. Ordinary Shares, no par value per share (QNRX).
- Disclosed ownership: 9.5%.
- Date of event: 31 Dec 2025.
Woodline Partners LP - 31 Dec 2025 SCHEDULE 13G Report for Quoin Pharmaceuticals, Ltd. Ordinary Shares, no par value per share (QNRX)
- Filing Manager
- Woodline Partners LP
- Reporting Manager
- Woodline Partners LP
- Symbol
- QNRX
- Shares outstanding
- 29,319,684 shares
- Disclosed Ownership
- 2,785,370 shares
- Ownership
- 9.5%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Feb 2026, 15:20:10 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Woodline Partners LP disclosed 9.5% ownership in Quoin Pharmaceuticals, Ltd. Ordinary Shares, no par value per share (QNRX) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 15:20.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Woodline Partners LP | 9.5% | 2,785,370 | 2,785,370 | 0 | /s/ Erin Mullen | Erin Mullen, General Counsel & Chief Compliance Officer |